同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处 罚事先告知书》，因贵州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券 交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票 自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。 自2025年 12月23日开市起，贵州百灵股票简称由"贵州百灵" 变更为"ST百灵" ，股票代码不变，仍 为"002424"，股票交易日涨跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 贵州百灵财务造假遭重罚 对此你有什么想说的？ 欢迎评论区聊聊~ （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品丨21财经客户端 21世纪经济报道 理想汽车组织架构调整，涉近千人，原零部件负责人离职 热搜第一，牛股瞬间闪崩12个点，网友：炒股用曲面屏太难受 SFC 21君荐读 记者丨曾静娇 编辑丨刘雪莹 12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限 公司(以下简称"贵州百灵")涉嫌定期 ...

Zacks Investment Research has recently initiated coverage of Cumberland Pharmaceuticals Inc. (CPIX) with an “Outperform” recommendation, citing the company’s differentiated specialty pharmaceutical model, durable revenue opportunities and multiple long-term growth drivers.Cumberland Pharmaceuticals is a Nashville-based specialty pharma company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology markets. The company’s strate ...

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is receiving increased attention from analysts, with multiple firms issuing positive ratings and price targets, indicating a favorable outlook for the company [2][3]. Analyst Ratings - Jefferies reiterated a Buy rating with a price target of $68 on December 4th, while Scotiabank raised its target from $45 to $53, maintaining a Sector Perform rating [2]. - Guggenheim set a price target of $62 with a Buy rating on December 12th, reflecting optimism about the company's pipeline [2]. Regulatory Developments - The FDA granted traditional approval to Bristol-Myers' Breyanzi drug for certain patients with relapsed or refractory marginal zone lymphoma on December 4th [3]. - On December 11th, the FDA also granted Priority review to Opdivo for the treatment of Hodgkin lymphoma, further enhancing the company's regulatory profile [3]. Market Context - Jim Cramer discussed Bristol-Myers in relation to broader drug stocks, suggesting that the stock could see higher multiples despite a lack of new developments [4]. - The commentary indicates a belief that the market may be willing to assign higher valuations to drug stocks, including Bristol-Myers, in the current environment [4].

We recently published 12 Stocks on Jim Cramer’s Radar.  Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer's radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The figures saw Pfizer Inc. (NYSE:PFE) forecast 2026 revenue to range between $59.5 billion to $62.5 billion and profit per share between $2.80 and $3. Both of these were below LSEG ...

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) is experiencing a positive shift in its stock performance due to successful drug trials and optimistic analyst ratings, particularly in light of its upcoming patent expirations for Keytruda [2][3]. Group 1: Company Performance - Merck's shares have remained flat year-to-date but saw a positive run starting November 3rd, attributed to successful catalysts [2]. - The company announced successful phase two trials for its heart drug Winrevair on November 18th, allowing it to proceed to phase three studies [2]. - The success of Winrevair is crucial for Merck as it seeks to sustain revenue following the impending patent expirations of its cancer drug Keytruda [2]. Group 2: Analyst Ratings - Bank of America raised Merck's share price target to $120 from $105, maintaining a Buy rating based on new estimates for FY27 EPS [3]. - Morgan Stanley, while reiterating an Equal Weight rating, raised its price target to $102 from $100 [3]. - Jim Cramer expressed optimism about Merck's stock potential, suggesting it has a "better hand" compared to competitors [3].

We recently published 12 Stocks on Jim Cramer’s Radar.  Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer's radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December so far. During this time period, Johnson & Johnson (NYSE:JNJ) has reported several important developments. For instance, the firm announced on December 12th that it had secur ...

Core Insights - Gilead Sciences, Inc. (GILD) maintains a leading position in the HIV market, primarily driven by its flagship therapies Biktarvy and Descovy, which have significantly contributed to the company's revenue growth in recent quarters [1][9] Gilead's HIV Portfolio - The FDA approved lenacapavir, branded as Yeztugo, as the first and only twice-yearly injectable HIV-1 capsid inhibitor for prevention, enhancing GILD's HIV portfolio amid generic competition for Truvada [2][9] - Yeztugo's competitive edge lies in its biannual dosing, appealing to a broader population compared to daily oral medications [3] - Gilead's investigational single-tablet regimen combining bictegravir and lenacapavir has met primary endpoints in phase III studies, indicating potential for regulatory submission [4][5] Competitive Landscape - The HIV treatment market includes major competitors like GSK and Merck, with GSK's HIV portfolio benefiting from strong demand for long-acting injectables and Dovato, while Merck markets doravirine in various formulations [7][8][10] Financial Performance - Gilead's stock has increased by 31.2% over the past year, outperforming the industry average growth of 15% [11] - The company's shares are trading at a price/earnings ratio of 14.32x forward earnings, which is above its historical mean of 10.93x but below the large-cap pharma industry's average of 17.11x [12] - Earnings estimates for 2025 have risen to $8.17 from $8.07, while the estimate for 2026 has slightly decreased to $8.50 from $8.51 [13]

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [2]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

- New Patent Expands IGC Pharma's Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer's Disease - POTOMAC, MD / ACCESS Newswire / December 19, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office (USPTO) has officially issued U.S. Patent No. 12,491,200, covering the Company's novel microd ...

Core Insights - Amplia Therapeutics Limited has entered the second phase of a research collaboration with Next & Bio to further investigate the efficacy of its FAK inhibitors in treating pancreatic cancer [2][3][4] - The collaboration aims to explore the synergistic effects of Amplia's FAK inhibitor narmafotinib in combination with kRAS inhibitors, which target genetic mutations present in over 90% of pancreatic cancers [3][4][9] - Initial studies have shown that narmafotinib demonstrated promising activity against patient-derived pancreatic cancer cells, with plans to present this data at an upcoming scientific conference [3][6] Company Overview - Amplia Therapeutics is an Australian pharmaceutical company focused on developing a pipeline of FAK inhibitors for cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [7] - Narmafotinib (AMP945) is Amplia's leading FAK inhibitor, which has shown significant potential in preclinical studies and is currently undergoing clinical trials in combination with established chemotherapies [8][10] Collaboration Details - The partnership with Next & Bio, a preclinical drug screening company, leverages patient-derived cell models to provide more accurate and predictive results for pancreatic cancer treatment [5][6] - The collaboration is expected to enhance Amplia's strategic positioning for future partnerships and commercial growth opportunities [6]